secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275871
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set
------------------------------------------------------------------------

- Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.
- Received $60M upfront from Incyte for exclusive option on JAK2V617F inhibitor; cash runway into 2027.
- JAK2V617F JH2 inhibitor IND filing expected Q1 2026; oral KAT6A degrader IND mid-2026.
- Preclinical data for JAK2 inhibitor and mCALR DAC accepted for oral ASH Dec 2025 presentations.
- Expanded AbCellera collaboration; additional license payment received in Oct 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/0001193125-25-275871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/prld-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer